Ethynodiol diacetate

Identification

Name
Ethynodiol diacetate
Accession Number
DB00823  (APRD00760)
Type
Small Molecule
Groups
Approved
Description

A synthetic progestational hormone used alone or in combination with estrogens as an oral contraceptive. Although etynodiol or ethynodiol are sometimes used as a synonym for ethynodiol diacetate, what is usually being referred to is actually ethynodiol diacetate and not ethynodiol (which is a separate drug that has never been marketed, see Ethynodiol).

Structure
Thumb
Synonyms
  • 17α-Ethynyl-19-norandrost-4-ene-3β,17-beta-diol diacetate
  • 17α-Ethynyl-3,17-dihydroxy-4-estrene diacetate
  • 17α-Ethynyl-4-estrene-3β,17β-diol diacetate
  • 17α-Ethynylestr-4-ene-3β,17β-diol acetate
  • 19-Nor-17α-pregn-4-en-20-yne-3β,17-diol diacetate
  • 3β, 17β-Diacetoxy-17α-ethynyl-4-oestrene
  • 3β,17β-Diacetoxy-19-nor-17α-pregn-4-en-20-yne
  • Etynodiol acetate
  • Etynodiol diacetate
External IDs
CB 8080 / SC 11800 / SC-11800
Product Images
International/Other Brands
Conova (Searle) / Continuin / Dernulen (Searle) / Femulen (Pfizer ) / Luteonorm / Luto-Metrodiol / Metrodiol
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Demulen 30 (21 Day Pack)Ethynodiol diacetate (2 mg) + Ethinyl Estradiol (30 mcg)TabletOralPfizer1979-12-31Not applicableCanada
Demulen 30 (28 Day Pack)Ethynodiol diacetate (2 mg) + Ethinyl Estradiol (30 mcg)TabletOralPfizer1979-12-31Not applicableCanada
Demulen 50 (21 Day Pack)Ethynodiol diacetate (1 mg) + Ethinyl Estradiol (50 mcg)TabletOralPfizer1970-12-312005-04-01Canada
Demulen 50 (28 Day Pack)Ethynodiol diacetate (1 mg) + Ethinyl Estradiol (50 mcg)TabletOralPfizer1970-12-312005-04-01Canada
Ethynodiol Diacetate and Ethinyl EstradiolEthynodiol diacetate + Ethinyl EstradiolKitMylan Pharmaceuticals2016-11-30Not applicableUs
Ethynodiol Diacetate and Ethinyl EstradiolEthynodiol diacetate + Ethinyl EstradiolKitMylan Pharmaceuticals2017-09-19Not applicableUs
Kelnor 1/35Ethynodiol diacetate + Ethinyl EstradiolKitA S Medication Solutions2005-06-202017-06-20Us
Kelnor 1/35Ethynodiol diacetate + Ethinyl EstradiolKitTeva2005-06-20Not applicableUs
Kelnor 1/35Ethynodiol diacetate + Ethinyl EstradiolKitPhysicians Total Care, Inc.2008-09-16Not applicableUs00555 9064 58 nlmimage10 0e368734
Zovia 1/35Ethynodiol diacetate + Ethinyl EstradiolKitMayne Pharma2016-07-18Not applicableUs
Categories
UNII
62H10A1236
CAS number
297-76-7
Weight
Average: 384.5085
Monoisotopic: 384.230059512
Chemical Formula
C24H32O4
InChI Key
ONKUMRGIYFNPJW-KIEAKMPYSA-N
InChI
InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1
IUPAC Name
(1S,2R,5S,10R,11S,14R,15S)-5-(acetyloxy)-14-ethynyl-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl acetate
SMILES

Pharmacology

Indication

For the prevention of pregnancy in women who elect to use this product as a method of contraception.

Structured Indications
Pharmacodynamics

Ethynodiol Diacetate is used as a female contraceptive. Ethynodiol Diacetate is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Ethynodiol Diacetate tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.

Mechanism of action

Binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Ethynodiol Diacetate will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.

TargetActionsOrganism
AProgesterone receptor
agonist
Human
AEstrogen receptor alpha
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

50-85%

Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Ethynodiol diacetate.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
AcenocoumarolEthynodiol diacetate may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ethynodiol diacetate.Investigational, Withdrawn
AcitretinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Acitretin.Approved
AdapaleneThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Ethynodiol diacetate.Experimental, Investigational
AlitretinoinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Alitretinoin.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Ethynodiol diacetate.Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethynodiol diacetate.Approved
AmobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Amobarbital.Approved, Illicit
AprepitantThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Aprepitant.Approved, Investigational
ArtemetherThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Artemether.Approved
AtazanavirThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Atazanavir.Approved, Investigational
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ethynodiol diacetate.Investigational
BarbexacloneThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Barbital.Illicit
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Ethynodiol diacetate.Investigational
BexaroteneThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Bosentan.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Ethynodiol diacetate.Investigational, Withdrawn
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethynodiol diacetate.Approved
CarbamazepineThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Carbamazepine.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Ethynodiol diacetate.Experimental
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ethynodiol diacetate.Experimental
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ethynodiol diacetate.Approved
CholestyramineThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Cholestyramine.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ethynodiol diacetate.Experimental
ClobazamThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Clobazam.Approved, Illicit
ClorindioneEthynodiol diacetate may decrease the anticoagulant activities of Clorindione.Experimental
CobicistatThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Cobicistat.Approved
ColesevelamThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Colestipol.Approved
DabrafenibThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Darunavir.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Ethynodiol diacetate.Investigational
DicoumarolEthynodiol diacetate may decrease the anticoagulant activities of Dicoumarol.Approved
DiphenadioneEthynodiol diacetate may decrease the anticoagulant activities of Diphenadione.Experimental
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ethynodiol diacetate.Approved
EfavirenzThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Efavirenz.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethynodiol diacetate.Approved
Eslicarbazepine acetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Eslicarbazepine acetate.Approved
Ethyl biscoumacetateEthynodiol diacetate may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Exenatide.Approved, Investigational
FelbamateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Felbamate.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ethynodiol diacetate.Approved
FluindioneEthynodiol diacetate may decrease the anticoagulant activities of Fluindione.Investigational
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Ethynodiol diacetate resulting in a loss in efficacy.Approved
FosaprepitantThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Fosaprepitant.Approved
FosphenytoinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Fosphenytoin.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ethynodiol diacetate.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Ethynodiol diacetate.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethynodiol diacetate.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Ethynodiol diacetate.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Ethynodiol diacetate.Approved
GriseofulvinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Griseofulvin.Approved, Vet Approved
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ethynodiol diacetate.Investigational
HexobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Hexobarbital.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ethynodiol diacetate.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ethynodiol diacetate.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ethynodiol diacetate.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ethynodiol diacetate.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ethynodiol diacetate.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ethynodiol diacetate.Approved
IsotretinoinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Isotretinoin.Approved
LamotrigineThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lamotrigine.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Ethynodiol diacetate.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Ethynodiol diacetate.Approved
LopinavirThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lopinavir.Approved
LumacaftorThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lumacaftor.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ethynodiol diacetate.Approved
MethohexitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Methylphenobarbital.Approved
MetreleptinThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Metreleptin.Approved
MifepristoneThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ethynodiol diacetate.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Ethynodiol diacetate.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
Mycophenolic acidThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Mycophenolic acid.Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
NelfinavirThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Nelfinavir.Approved
NevirapineThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Nevirapine.Approved
OxcarbazepineThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Oxcarbazepine.Approved
PentobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Pentobarbital.Approved, Vet Approved
PerampanelThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Perampanel.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational, Withdrawn
PhenindioneEthynodiol diacetate may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Phenobarbital.Approved
PhenprocoumonEthynodiol diacetate may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
PrimidoneThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Primidone.Approved, Vet Approved
PrucaloprideThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Prucalopride.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
RifabutinThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Rifaximin.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
SaquinavirThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ethynodiol diacetate.Approved
SecobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Ethynodiol diacetate.Approved, Investigational, Vet Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Ethynodiol diacetate.Investigational
St. John's WortThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with St. John's Wort.Investigational, Nutraceutical
SugammadexThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Sugammadex.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
TelaprevirThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Telaprevir.Approved, Withdrawn
ThalidomideEthynodiol diacetate may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Thiopental.Approved, Vet Approved
TioclomarolEthynodiol diacetate may decrease the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Tipranavir.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ethynodiol diacetate.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethynodiol diacetate.Approved
TopiramateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Topiramate.Approved
Tranexamic AcidEthynodiol diacetate may increase the thrombogenic activities of Tranexamic Acid.Approved
TretinoinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Ethynodiol diacetate.Investigational, Withdrawn
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
VoriconazoleThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinEthynodiol diacetate may decrease the anticoagulant activities of Warfarin.Approved
Food Interactions
Not Available

References

Synthesis Reference

Klimstra, P.D.; U.S. Patent 3,176,013; March 30, 1965; assigned to G.D. Searle & Co.

General References
Not Available
External Links
Human Metabolome Database
HMDB14961
KEGG Drug
D01294
KEGG Compound
C12724
PubChem Compound
9270
PubChem Substance
46506993
ChemSpider
8913
ChEBI
31580
ChEMBL
CHEMBL1200624
Therapeutic Targets Database
DAP000856
PharmGKB
PA164749157
RxList
RxList Drug Page
Wikipedia
Ethynodiol_diacetate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceTherapeutic Equivalency1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral
Kit
KitOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)126-127Klimstra, P.D.; U.S. Patent 3,176,013; March 30, 1965; assigned to G.D. Searle & Co.
logP5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00397 mg/mLALOGPS
logP3.99ALOGPS
logP3.69ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)-6.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.62 m3·mol-1ChemAxon
Polarizability44.11 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9907
Blood Brain Barrier+0.9399
Caco-2 permeable+0.6125
P-glycoprotein substrateSubstrate0.5754
P-glycoprotein inhibitor IInhibitor0.8432
P-glycoprotein inhibitor IIInhibitor0.619
Renal organic cation transporterNon-inhibitor0.8131
CYP450 2C9 substrateNon-substrate0.8497
CYP450 2D6 substrateNon-substrate0.9139
CYP450 3A4 substrateSubstrate0.7647
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.6524
CYP450 2D6 inhibitorNon-inhibitor0.9519
CYP450 2C19 inhibitorNon-inhibitor0.7671
CYP450 3A4 inhibitorNon-inhibitor0.6564
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8322
Ames testNon AMES toxic0.9651
CarcinogenicityNon-carcinogens0.9119
BiodegradationNot ready biodegradable0.963
Rat acute toxicity2.1783 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9037
hERG inhibition (predictor II)Non-inhibitor0.8353
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Estrane steroids / Delta-4-steroids / Ynones / Dicarboxylic acids and derivatives / Carboxylic acid esters / Acetylides / Organic oxides / Hydrocarbon derivatives
Substituents
Steroid ester / Estrane-skeleton / Delta-4-steroid / Ynone / Dicarboxylic acid or derivatives / Carboxylic acid ester / Acetylide / Carboxylic acid derivative / Organic oxygen compound / Organic oxide
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
terminal acetylenic compound, steroid ester (CHEBI:31580) / C21 steroids (gluco/mineralocorticoids, progestogens) and derivatives (C12724) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030124)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Tamaya T, Nioka S, Furuta N, Shimura T, Takano N: Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84. [PubMed:858280]
  2. Briggs MH: Contraceptive steroid binding to the human uterine progesterone-receptor. Curr Med Res Opin. 1975;3(2):95-8. [PubMed:166800]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Kappus H, Bolt HM, Remmer H: Affinity of ethynyl-estradiol and mestranol for the uterine estrogen receptor and for the microsomal mixed function oxidase of the liver. J Steroid Biochem. 1973 Mar;4(2):121-8. [PubMed:4123746]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:43